Balanced Risk-Reward Amid Growth Ambitions and Margin Rebuild Supports Humana Hold Rating

TD Cowen analyst Ryan Langston maintained a Hold rating on Humana today and set a price target of $173.00.

Ryan Langston has given his Hold rating due to a combination of factors tied to Humana’s growth outlook and profitability profile. While the company is targeting at least $9 per share in adjusted EPS for FY26 and projecting roughly 25% growth in Individual MA enrollment, he is wary about the execution risk of integrating such rapid membership expansion while still trying to rebuild core margins, which tempers upside to his $173 price target.

At the same time, he recognizes meaningful positives, including materially better member retention during the 2026 AEP, a healthier sales mix skewed toward more engaged, durable members, and structural product changes that should improve lifetime value and support margin recovery through 2028 despite a sizable Stars-related headwind. Management’s confidence in regaining top-quartile Stars performance and its advocacy for reimbursement rates that better match cost trends are encouraging, but until these initiatives translate more visibly into earnings and margin stability, the risk‑reward profile appears balanced rather than compelling, supporting a Hold stance.

Langston covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, Centene, and HCA Healthcare. According to TipRanks, Langston has an average return of -10.7% and a 33.04% success rate on recommended stocks.